1-3 of 3
Samuel Litwin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Natural Killer Cell Dysfunction in Chronic Lymphocytic Leukemia Is Associated with Loss of the Mature KIR3DL1 + Subset

Alexander W. MacFarlane, PhD, Mowafaq Jillab, MD, Mitchell R Smith, MD PhD, R. Katherine Alpaugh, PhD, Marion E. Cole, MD, Samuel Litwin, PhD, Michael M. Millenson, MD, Tahseen I. Al-Saleem, MD, Adam D. Cohen, MD, Kerry S. Campbell, PhD
Journal: Blood
Blood (2014) 124 (21): 3318.
https://doi.org/10.1182/blood.V124.21.3318.3318
Published: 2014
Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2753.
https://doi.org/10.1182/blood.V120.21.2753.2753
Published: 2012
Journal Articles

Peripheral Blood CD3 + CD4 + and CD3 − CD56 + Cell Counts and Circulating Lymphoma Cells Are Significant Predictors of Overall Survival in Newly Diagnosed Follicular Lymphoma.

Danielle Shafer, DO, Mitchell R. Smith, MD, PhD, Samuel Litwin, PhD, Tianyu Li, Hossein Borghaei, DO, Tahseen I. Al-Saleem, MD
Journal: Blood
Blood (2007) 110 (11): 2607.
https://doi.org/10.1182/blood.V110.11.2607.2607
Published: 2007